Relvar

Type: Product
Name: Relvar
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

Data Published on Anoro(R) Ellipta(R) Demonstrate Improved Lung Function Compared to Tiotropium

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Oct 17, 2014) - Theravance, Inc. ( NASDAQ : THRX ) --  Respiratory Medicine has published positive results from a third lung function study comparing the efficacy and safety of Anoro ® ... [Published MarketWired - Oct 17 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 2 reports

Global Fluticasone Furoate (Asthma) Market: New market analysis published

(live-PR.com) - Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023 The PharmaPoint Drug Evaluation report has just been released titled, "Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very ... [Published Live-PR.com - Oct 17 2014]
First reported Oct 14 2014 - Updated Oct 15 2014 - 1 reports

Research and Markets: GSK's Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/bpqm6w/fluticasone) has announced the addition of the "Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023" report to their offering. GSK's fluticasone ... [Published Business Wire Health News - Oct 14 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

GlaxoSmithKline Expands In North Carolina With Hiring Spree

October 14, 2014By Mark Terry , BioSpace.com Breaking News StaffIn light of several U.S. Food and Drug Administration approvals for respiratory drugs, GlaxoSmithKline ( GSK ) plans to expand production and hiring at its Zebulon facility in North Caro ... [Published BioSpace - Oct 14 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

Research and Markets: Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/jtzb9k/breo_ellipta) has announced the addition of the "Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023" report to their offering. Breo Ellipta (or ... [Published Business Wire Health News - Oct 14 2014]
First reported Oct 13 2014 - Updated Oct 13 2014 - 1 reports

Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023

is a new market research publication announced by . The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids ... [Published MyNewsDesk - Oct 13 2014]
First reported Oct 09 2014 - Updated Oct 10 2014 - 1 reports

Theravance, Inc. Appoints Eric d'Esparbes as Senior Vice President and Chief Financial Officer

- Theravance, Inc. ( NASDAQ : THRX ) today announced the appointment of Eric d'Esparbes as Senior Vice President and Chief Financial Officer. Mr. d'Esparbes will report directly to Michael W. Aguiar, Chief Executive Officer, and be responsible for overseeing ... [Published Stockboard Media Inc. - Oct 09 2014]
First reported Oct 08 2014 - Updated Oct 08 2014 - 1 reports

The Asthma Market Is Forecast to Remain Stable over the Next Decade, Despite Generic Erosion of Market Leading Asthma Therapies

BURLINGTON, Mass., Oct. 8, 2014 /PRNewswire/ -- Decision Resources Group finds that the market for asthma will remain stable, increasing slightly from $15.1 billion in 2013 to $16.1 billion in 2023 in the United States, France, Germany, Italy, Spain, ... [Published BusinessWeek - Oct 08 2014]
First reported Sep 13 2014 - Updated Sep 13 2014 - 1 reports

Vectura Group Following A Familiar Path

Summary Vectura Group isn't well-known, but it has a broad and deep portfolio of patents and technology for the formulation, manufacture, and administration of respiratory drugs. Novartis's Ultibro and Seebri are selling well in the EU and Ultibro could ... [Published Seeking Alpha - Sep 13 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Human medicines European public assessment report (EPAR): Relvar Ellipta, fluticasone furoate / vilanterol, Revision: 1, Authorised

Entities: Relvar, Ellipta, Humanism
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma

BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first ... [Published PR Newswire: General Business - Jul 24 2014]
Entities: Relvar, Asthma, Experience
First reported Jun 11 2014 - Updated Jun 12 2014 - 1 reports

GSK and Theravance Announce Positive Data From Two Studies Evaluating the Efficacy and Safety of Incruse(TM) Ellipta(R) When Added to Relvar(R)/Breo(R) Ellipta(R) in Patients With COPD

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 11, 2014) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from two phase III studies, which showed that patients ... [Published Marketwire - Breaking News Releases - Jun 11 2014]

Quotes

...Other risks affecting Theravance are described under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" contained in Theravance's Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 filed with the Securities and Exchange Commission (SEC) on...
...us to provide increasing capital returns to shareholders over time," said Michael W Aguiar, President and Chief Executive Officer of Theravance. "We are pleased to have Eric join our company and believe he compliments our new leadership team focused on building long-term value for shareholders."
...However, this will ultimately constrain the sales potential of the overall asthma market. "Launch of the first anti-interleukin-5 agent specifically targeting severe asthma patients with high levels of eosinophils will mean not only addressing the unmet needs of severe asthma patients who are refractory to available asthma therapies but also mark the beginning of a new era of more personalized medicine in the heterogeneous asthma patient population with a biomarker-driven therapeutic approach. Uptake of these expensive biological therapies, including anti-IL-5 and anti-IL-13 agents, will partly rely on the validity and ease of use of their corresponding biomarker tests and the reimbursement of such tests."
"Completion of the Capital Raise and the repayment of all of Skyepharma's bond debt has transformed the Group's balance sheet and will enable us to invest in new products, technologies and other corporate opportunities."

More Content

All (23) | News (16) | Reports (0) | Blogs (7) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Data Published on Anoro(R) Ellipta(R) Demonstra... [Published MarketWired - Oct 17 2014]
Global Fluticasone Furoate (Asthma) Market: New... [Published Live-PR.com - Oct 17 2014]
Global Breo Ellipta (Asthma) Market: New market... [Published Live-PR.com - Oct 17 2014]
GlaxoSmithKline Expands In North Carolina With ... [Published BioSpace - Oct 14 2014]
Research and Markets: Breo Ellipta (Asthma) - F... [Published Business Wire Health News - Oct 14 2014]
Research and Markets: GSK's Fluticasone Furoate... [Published Business Wire Health News - Oct 14 2014]
Breo Ellipta (Asthma) - Forecast and Market Ana... [Published Individual.com - Oct 14 2014]
Fluticasone Furoate (Asthma) - Forecast and Mar... [Published MyNewsDesk - Oct 13 2014]
Theravance, Inc. Appoints Eric d'Esparbes as Se... [Published Stockboard Media Inc. - Oct 09 2014]
The Asthma Market Is Forecast to Remain Stable ... [Published BusinessWeek - Oct 08 2014]
The Asthma Market Is Forecast to Remain Stable ... [Published BioSpace - Oct 08 2014]
Vectura Group Following A Familiar Path [Published Seeking Alpha - Sep 13 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 13 2014]
Surveyed EU5 Pulmonologists Expect that Relvar,... [Published PR Newswire: General Business - Jul 24 2014]
Theravance, Inc. Appoints Theodore J. Witek, Jr... [Published Marketwire - Breaking News Releases - Jul 02 2014]
Theravance, Inc. Appoints George B. Abercrombie... [Published Marketwire - Breaking News Releases - Jun 12 2014]
GSK and Theravance Announce Positive Data From ... [Published Marketwire - Breaking News Releases - Jun 11 2014]
Interim Management Statement [Published TrustNet - May 16 2014]
1st Quarter Results [Published TrustNet - Apr 30 2014]
Welcome tonic [Published Engineer Online - Apr 23 2014]
Proposed Placing and Open Offer to Raise ?112m [Published TrustNet - Mar 31 2014]
Anoro receives Positive Opinion from the CHMP [Published Vitec Group - Mar 27 2014]
Final Results [Published TrustNet - Feb 05 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Research and Markets: Breo Ellipta (Asthma) - F... [Published Business Wire Health News - Oct 14 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/jtzb9k/breo_ellipta) has announced the addition of the "Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023" report to their offering. Breo Ellipta (or ...
Research and Markets: GSK's Fluticasone Furoate... [Published Business Wire Health News - Oct 14 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/bpqm6w/fluticasone) has announced the addition of the "Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023" report to their offering. GSK's fluticasone ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 13 2014]
Surveyed EU5 Pulmonologists Expect that Relvar,... [Published PR Newswire: General Business - Jul 24 2014]
BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first ...
Theravance, Inc. Appoints Theodore J. Witek, Jr... [Published Marketwire - Breaking News Releases - Jul 02 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Jul 2, 2014) - Theravance, Inc. (NASDAQ: THRX) ("Theravance"), A Royalty Management Company, today announced the appointment of Theodore J. Witek, Jr. as Senior Vice President Corporate Partnerships, Clinical ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.